adenocarcinoma

(redirected from adenocarcinoma in situ)
Also found in: Thesaurus, Medical, Acronyms, Encyclopedia.

ad·e·no·car·ci·no·ma

 (ăd′n-ō-kär′sə-nō′mə)
n.
A malignant tumor originating in glandular tissue.

ad′e·no·car′ci·nom′a·tous (-nŏm′ə-təs, -nō′mə-təs) adj.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

adenocarcinoma

(ˌædɪnəʊˌkɑːsɪˈnəʊmə)
n, pl -mas or -mata (-mətə)
1. (Pathology) a malignant tumour originating in glandular tissue
2. (Pathology) a malignant tumour with a glandlike structure
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

ad•e•no•car•ci•no•ma

(ˌæd n oʊˌkɑr səˈnoʊ mə)

n., pl. -mas, -ma•ta (-mə tə)
1. a malignant tumor arising from secretory epithelium.
2. a malignant tumor of glandlike structure.
[1885–90]
ad`e•no•car`ci•nom′a•tous (-ˈnɒm ə təs, -ˈnoʊ mə-) adj.
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.adenocarcinoma - malignant tumor originating in glandular epitheliumadenocarcinoma - malignant tumor originating in glandular epithelium
carcinoma - any malignant tumor derived from epithelial tissue; one of the four major types of cancer
prostate cancer, prostatic adenocarcinoma - cancer of the prostate gland
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
Translations

ad·e·no·car·ci·no·ma

n. adenocarcinoma, cáncer maligno que se origina en una glándula.
English-Spanish Medical Dictionary © Farlex 2012

adenocarcinoma

n adenocarcinoma m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
CT, computed tomography; AIS, adenocarcinoma in situ; GGN, ground-glass nodules; mi, minimally invasive; PL1, tumor invasion of the elastic layer of visceral pleura without reaching the visceral pleural surface; PL2, tumor invasion of the visceral pleural surface; PL3, tumor invasion of the parietal pleura or chest wall.
(41-47) Currently, it is postulated that GEA might develop from a series of precursor lesions that begin with gastric metaplasia at one end of the spectrum, and proceed through LEGH, atypical LEGH, gastric type adenocarcinoma in situ, and finally to invasive carcinoma.
Takagi, "Epidermal growth factor receptor mutations in adenocarcinoma in situ and minimally invasive adenocarcinoma detected using mutation-specific monoclonal antibodies," Lung Cancer, vol.
Consequently, a diagnosis of adenocarcinoma in situ arising from Brunner's glands was made.
Endocervical adenocarcinoma in situ and Invasive adenocarcinoma of the cervix were the least common.
An additional comment by the pathologist suggested that endocervical glandular dysplasia or adenocarcinoma in situ could not be ruled out.
This is the case report of rare, vulva primary villoglandular mucinous adenocarcinoma in situ. This disease is more commonly known as adenocarcinoma of cloacogenic origin, enteric type adenocarcinoma, or cloacogenic adenocarcinoma [1-12].
In accordance with the revised criteria of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) [3], lung adenocarcinoma was classified as adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), or invasive adenocarcinoma (IAC).
The relatively recent documentation that women with a history of CIN 2 or 3 (and probably adenocarcinoma in situ) remain at risk of developing cervical cancer for at least 20 years after treatment warrants annual screening for at least 20 years.
A 1999 Kaiser Permanente study of 137 women with cytologic atypical glandular cells (AGC) found that HPV DNA testing identified 94% of those with high-grade squamous intraepithelial lesions (HSIL) and 100% of those with endocervical adenocarcinoma in situ (Hum.